FibroGen, Inc. (NASDAQ:FGEN) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure
On June7, 2018, FibroGen, Inc. (the “Company”) conducted a fireside chat at the Jefferies 2018 Global Health Care Conference.
A copy of the transcript of the chat is furnished as Exhibit99.1 to this report and is incorporated herein by reference.
The information in this Item 7.01 is being furnished, not filed, to Regulation FD. Accordingly, the information in Item 7.01 of this report will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this report is not intended to, and does not, constitute a determination or admission by the Company that the information in this report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.
Item 7.01 Financial Statements and Exhibits.
(d) Exhibits
FIBROGEN INC ExhibitEX-99.1 2 d791373dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 MY (Michael Yee,…To view the full exhibit click here
About FibroGen, Inc. (NASDAQ:FGEN)
FibroGen, Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200. FG-4592 is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylases (HIF-PHs), which acts by stimulating the body’s natural pathway of erythropoiesis or red blood cell production. FG-4592 is in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). FG-3019 is a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD) and liver fibrosis. FG-6874 is in Phase I clinical trials, and FG-5200 is a corneal implant medical device, which is in preclinical studies.
